187 related articles for article (PubMed ID: 26145175)
1. MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
Zhang X; Schulz R; Edmunds S; Krüger E; Markert E; Gaedcke J; Cormet-Boyaka E; Ghadimi M; Beissbarth T; Levine AJ; Moll UM; Dobbelstein M
Mol Cell; 2015 Jul; 59(2):243-57. PubMed ID: 26145175
[TBL] [Abstract][Full Text] [Related]
2. NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein.
Waku T; Nakamura N; Koji M; Watanabe H; Katoh H; Tatsumi C; Tamura N; Hatanaka A; Hirose S; Katayama H; Tani M; Kubo Y; Hamazaki J; Hamakubo T; Watanabe A; Murata S; Kobayashi A
Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123008
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
4. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
Prenzel T; Begus-Nahrmann Y; Kramer F; Hennion M; Hsu C; Gorsler T; Hintermair C; Eick D; Kremmer E; Simons M; Beissbarth T; Johnsen SA
Cancer Res; 2011 Sep; 71(17):5739-53. PubMed ID: 21862633
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
7. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
8. Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Gu Y; Bouwman P; Greco D; Saarela J; Yadav B; Jonkers J; Kuznetsov SG
Cell Death Dis; 2014 Dec; 5(12):e1580. PubMed ID: 25522274
[TBL] [Abstract][Full Text] [Related]
9. Blocking Cancer Growth with Less POMP or Proteasomes.
Goldberg AL; Zhao J; Collins GA
Mol Cell; 2015 Jul; 59(2):143-5. PubMed ID: 26186288
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
12. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
[TBL] [Abstract][Full Text] [Related]
13. The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.
Zieba BA; Henry L; Lacroix M; Jemaà M; Lavabre-Bertrand T; Meunier L; Coux O; Stoebner PE
J Dermatol Sci; 2017 Oct; 88(1):10-19. PubMed ID: 28728908
[TBL] [Abstract][Full Text] [Related]
14. The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.
Li B; Fu J; Chen P; Ge X; Li Y; Kuiatse I; Wang H; Wang H; Zhang X; Orlowski RZ
J Biol Chem; 2015 Dec; 290(50):29854-68. PubMed ID: 26483548
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21.
Shen Y; Lu L; Xu J; Meng W; Qing Y; Liu Y; Zhang B; Hu H
Cell Biol Int; 2013 Oct; 37(10):1114-21. PubMed ID: 23716467
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
17. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
18. Melatonin as a proteasome inhibitor. Is there any clinical evidence?
Vriend J; Reiter RJ
Life Sci; 2014 Oct; 115(1-2):8-14. PubMed ID: 25219883
[TBL] [Abstract][Full Text] [Related]
19. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells.
Chang HY; Huang TC; Chen NN; Huang HC; Juan HF
Cell Death Dis; 2014 Nov; 5(11):e1540. PubMed ID: 25429617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
